Bariatric surgery tied to more weight loss than Wegovy, Zepbound

Bariatric surgery may confer greater long-term weight loss than semaglutide or tirzepatide for adults with obesity, according to data from a real-world study published in Obesity.
Karan R. Chhabra, MD, MSc, assistant professor of surgery and population health at NYU Grossman School of Medicine, said prior studies comparing weight loss with GLP-1 receptor agonists to bariatric surgery tend to be indirect comparisons or include older GLP-1s. Additionally, Chhabra said, weight loss in clinical trials for obesity drugs tends to be much higher than what health care professionals see from patients




